| Literature DB >> 34096330 |
Alexander C Razavi1,2, Lydia A Bazzano1,2, Jiang He1,2, Marie Krousel-Wood1,2, Jing Chen1,2, Camilo Fernandez1,2, Seamus P Whelton3, Tanika N Kelly1,2.
Abstract
Background Early identification of healthy arterial aging versus premature atherosclerosis is important for optimal atherosclerotic cardiovascular disease risk stratification and prevention. We sought to identify predictors for the long-term absence of carotid plaque among young adults. Methods and Results We included 508 participants from the Bogalusa Heart Study without clinical atherosclerotic cardiovascular disease who were free of carotid plaque at baseline (2001-2002) and underwent ultrasound imaging at follow-up (2013-2016). Modified Poisson regression estimated the persistent absence of plaque over 12.8 years. Participants were on average age 36.2 years at baseline, 64% were women, and 29% were Black. Although nearly all participants (97%) had a 10-year atherosclerotic cardiovascular disease risk <7.5%, there were 162 people (32%) who developed premature atherosclerosis. Aside from younger age (risk ratio [RR], 1.21; 95% CI, 1.07-1.36, per 10 years) and a total cholesterol/high-density lipoprotein cholesterol ratio <3.5 (RR, 1.15; 95% CI, 1.01-1.30), normal values of traditional risk factors did not predict long-term absence of plaque. Independent from traditional markers including glomerular filtration rate, serum calcium-phosphate product (RR, 1.07; 95% CI, 1.01-1.14, per 1-SD lower), phosphate (RR, 1.15; 95% CI, 1.03-1.29, per 1 mg/dL lower), and dietary sodium <2300 mg/day (RR, 1.20; 95% CI, 1.02-1.41) were significantly associated with the non-development of plaque. Conclusions Nearly one third of young adults with a low burden of traditional risk factors developed premature atherosclerosis. Beyond younger age and an ideal lipoprotein profile, lower calcium-phosphate homeostasis and low sodium intake were associated with long-term absence of carotid plaque. These results suggest that dietary and intrinsic minerals are early contributors to the development of arterial aging phenotypes.Entities:
Keywords: aging; carotid artery plaque; dietary sodium; phosphate; premature atherosclerosis
Mesh:
Substances:
Year: 2021 PMID: 34096330 PMCID: PMC8477892 DOI: 10.1161/JAHA.121.020774
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Characteristics of 508 BHS Participants Free of Carotid Plaque at the Baseline Visit
| Variable | All (n = 508) | Persistent Absence of Carotid Plaque (n = 346) | Premature Carotid Atherosclerosis (n = 162) | |
|---|---|---|---|---|
| Sociodemographic and lifestyle | ||||
| Age, y | 36.2 ± 4.4 | 35.8 ± 4.6 | 37.2 ± 3.9 | <0.001 |
| Women, % | 64.4 | 67.1 | 58.6 | 0.07 |
| Black, % | 29.3 | 29.5 | 29.0 | 0.91 |
| Post‐high school education, % | 62.4 | 65.6 | 55.6 | 0.03 |
| Never smokers, % | 60.0 | 64.2 | 51.9 | 0.008 |
| Dietary cholesterol, g/day | 254.5 (182.1‒335.8) | 254.5 (181.8‒334.4) | 252.3 (187.3‒338.4) | 0.70 |
| Dietary saturated fat, g/day | 23.5 (17.1‒31.3) | 23.3 (16.9‒30.6) | 23.9 (17.3‒32.1) | 0.41 |
| Dietary fat, g/day | 65.75 (49.1‒87.5) | 65.3 (48.3‒85.7) | 68.4 (49.8‒87.9) | 0.48 |
| Dietary fiber, g/day | 13.6 (9.7‒18.3) | 13.3 (9.7‒18.4) | 13.8 (9.8‒18.1) | 0.68 |
| Dietary sodium, mg/day | 2216.1 (1655.0‒2914.7) | 2137.0 (1646.9‒2921.6) | 2301.6 (1726.5‒2906.9) | 0.57 |
| Dietary potassium, mg/day | 2087.5 (1562.6‒2771.4) | 2076.8 (1545.1‒2795.9) | 2109.6 (1613.2‒2729.3) | 0.86 |
| Alcohol drinking, drinks/day | 0.0 (0.0‒0.4) | 0.0 (0.0‒0.4) | 0.0 (0.0‒0.6) | 0.06 |
| Physical activity, min/week | 45.0 (12.5‒90.0) | 45.0 (15.0‒80.0) | 45.0 (7.0‒120.0) | 0.39 |
| Cardiovascular imaging | ||||
| Baseline carotid intima‐media thickness, mm | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | <0.001 |
| Established ASCVD risk factors | ||||
| 10‐y ASCVD risk, %* | 0.7 (0.3, 1.7) | 0.5 (0.2, 1.3) | 1.0 (0.5, 2.6) | <0.001 |
| Systolic blood pressure, mm Hg | 114.7 ± 12.7 | 112.8 ± 12.0 | 118.7 ± 13.3 | <0.001 |
| Diastolic blood pressure, mm Hg | 77.6 ± 9.3 | 76.4 ± 8.9 | 80.2 ± 9.4 | <0.001 |
| Antihypertensive medication, % | 6.3 | 4.3 | 10.5 | 0.008 |
| Total cholesterol, mg/dL | 188.1 ± 34.2 | 184.7 ± 33.2 | 195.2 ± 35.3 | 0.001 |
| HDL cholesterol, mg/dL | 48.3 ± 12.1 | 49.0 ± 12.2 | 46.9 ± 11.7 | 0.07 |
| Apolipoprotein A1, mg/dL | 169.6 ± 31.3 | 170.1 ± 30.9 | 168.7 ± 32.2 | 0.66 |
| LDL cholesterol, mg/dL | 122.7 ± 30.7 | 119.5 ± 30.4 | 129.7 ± 30.3 | <0.001 |
| Apolipoprotein B, mg/dL | 83.8 ± 20.4 | 80.9 ± 18.7 | 90.0 ± 22.5 | <0.001 |
| Total cholesterol/HDL cholesterol | 4.1 ± 1.2 | 4.0 ± 1.2 | 4.4 ± 1.3 | <0.001 |
| LDL cholesterol/HDL cholesterol | 2.7 ± 1.0 | 2.6 ± 1.0 | 2.9 ± 1.1 | <0.001 |
| Apolipoprotein B/Apolipoprotein A1 | 0.5 ± 0.2 | 0.5 ± 0.1 | 0.6 ± 0.2 | <0.001 |
| Serum triglycerides, mg/dL* | 99.0 (72.0, 141.5) | 95.0 (71.0, 136.0) | 114.0 (75.0, 158.0) | 0.01 |
| Lipid‐lowering medication, % | 3.2 | 2.0 | 5.6 | 0.03 |
| Fasting blood glucose, mg/dL | 84.9 ± 19.5 | 84.1 ± 19.4 | 86.7 ± 19.7 | 0.18 |
| Glucose‐lowering medication, % | 1.4 | 1.2 | 1.9 | 0.69 |
| Waist circumference, cm | 92.3 ± 17.3 | 91.1 ± 17.3 | 94.6 ± 17.2 | 0.03 |
| Mineral metabolism | ||||
| eGFR, mL/min/1.73m2 | 105.2 ± 16.4 | 105.0 ± 16.2 | 105.5 ± 16.8 | 0.78 |
| Urine microalbumin, mg/L* | 7.0 (6.0, 13.0) | 7.0 (6.0, 12.0) | 9.0 (6.0, 14.0) | 0.11 |
| Serum calcium, mg/dL | 9.5 ± 0.4 | 9.5 ± 0.3 | 9.5 ± 0.4 | 0.30 |
| Serum phosphate, mg/dL | 3.4 ± 0.6 | 3.4 ± 0.6 | 3.5 ± 0.6 | 0.02 |
| Calcium‐phosphate product, mg2/dL2 | 32.7 ± 5.6 | 32.3 ± 5.7 | 33.6 ± 5.4 | 0.02 |
| Inflammatory markers | ||||
| Homocysteine, | 7.4 (6.2, 8.6) | 7.2 (6.2, 8.8) | 7.6 (6.3, 8.6) | 0.30 |
| Fibrinogen, mg/dL*,† | 255.0 (236.0, 272.0) | 255.0 (235.0, 270.0) | 254.0 (237.0, 276.0) | 0.65 |
All variables presented are baseline values unless otherwise noted.
Continuous variables are mean (SD) unless otherwise noted.
ASCVD indicates atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein cholesterol; and LDL, low‐density lipoprotein cholesterol.
Median (Q1–Q3).
Measured in subset of sample (homocysteine, 501; fibrinogen, 504).
Difference between long‐term absence of carotid plaque vspremature carotid atherosclerosis.
Figure 1Arterial aging phenotypes among people with normal values of traditional risk factors
TC indicates total cholesterol; and HDL‐C, high‐density lipoprotein cholesterol.
Figure 2Arterial aging phenotypes according to baseline 10‐year atherosclerotic cardiovascular disease risk
ASCVD indicates atherosclerotic cardiovascular disease.
Association of Demographics and Normal Values of Traditional ASCVD Risk Factors With the Persistent Absence of Carotid Plaque
| Variable | Relative Risk (95% CI) | |
|---|---|---|
| Demographic | ||
| Female sex | 1.01 (0.88‒1.16) | 0.92 |
| Black | 1.01 (0.88‒1.17) | 0.86 |
| Age, per 10 y younger | 1.21 (1.07‒1.36) | 0.003 |
| ASCVD risk factors | ||
| Never cigarette smoker | 1.12 (0.99‒1.28) | 0.08 |
| Waist circumference <40 in (men), <35 in (women) | 0.97 (0.85‒1.11) | 0.64 |
| Systolic BP <120 mm Hg and diastolic BP <80 mm Hg | 1.13 (0.98‒1.30) | 0.10 |
| Fasting blood glucose <100 mg/dL | 1.05 (0.78‒1.41) | 0.76 |
| Triglycerides <150 mg/dL | 1.10 (0.92‒1.32) | 0.29 |
| Total cholesterol/HDL‐C < 3.5 | 1.15 (1.01‒1.30) | 0.03 |
| 1.29 (1.04‒1.59) | 0.02 | |
Adjusted for age, sex, race, education, antihypertensive medication, lipid‐lowering medication, glucose‐lowering medication, cigarette smoking, waist circumference, blood pressure, fasting blood glucose, fasting serum triglycerides, and total cholesterol/high‐density lipoprotein cholesterol ratio.
ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; and HDL‐C, high‐density lipoprotein cholesterol.
>3 ideal atherosclerotic cardiovascular disease risk factors vs <3 ideal risk factors.
Association of Normal Values of Novel ASCVD Risk Factors and Lifestyle Behaviors with the Persistent Absence of Carotid Plaque
| Variable* | Relative Risk (95% CI) | |
|---|---|---|
| Inflammatory | ||
| Homocysteine <10 μmol/L | 0.98 (0.82‒1.16) | 0.79 |
| Fibrinogen, per 1‐SD lower | 1.00 (0.94‒1.06) | 0.99 |
| Renal and mineral metabolism | ||
| eGFR >90 mL/min/1.73 m2 | 0.98 (0.84‒1.15) | 0.83 |
| Urinary albumin <30 mg/L | 1.03 (0.84‒1.26) | 0.78 |
| Serum calcium, per 1 mg/dL lower | 1.04 (0.88, 1.24) | 0.66 |
| Calcium‐phosphate product, per 1‐SD lower | 1.07 (1.01‒1.15) | 0.03 |
| Serum phosphate, per 1 mg/dL lower | 1.15 (1.03‒1.29) | 0.01 |
| Lifestyle | ||
| Dietary sodium <2300 mg/day | 1.20 (1.02‒1.41) | 0.03 |
| Dietary potassium >3400 mg/day in men, >2600 mg/day in women | 0.99 (0.82‒1.19) | 0.88 |
| Dietary fiber >30 g/day | 1.20 (0.91‒1.58) | 0.20 |
| Dietary cholesterol <300 mg/day | 1.05 (0.89‒1.25) | 0.54 |
| Dietary saturated fat <10% of total calories | 1.04 (0.91‒1.19) | 0.59 |
| Moderate alcohol drinking† | 1.17 (0.91‒1.51) | 0.23 |
| Adequate physical activity† | 0.95 (0.79‒1.15) | 0.61 |
| 1.12 (0.98‒1.28) | 0.10 | |
Adjusted for age, sex, race, education, antihypertensive medication, lipid‐lowering medication, glucose‐lowering medication, cigarette smoking, waist circumference, blood pressure, fasting blood glucose, fasting serum triglycerides, and total cholesterol/high‐density lipoprotein cholesterol ratio.
ASCVD indicates atherosclerotic cardiovascular disease; and eGFR, estimated glomerular filtration rate.
Dietary risk markers and the cumulative lifestyle behavior risk score were also adjusted for total caloric intake.
<2 drinks/day in men, <1 drink/day in women, >150 min/wk of moderate activity or >75 min/wk of vigorous activity.
>3 ideal lifestyle behaviors vs <3 ideal lifestyle behaviors.